Next Phase Newsletter

A European VC firm has recently closed €75 million and is looking to make its first allocations. The firm is looking to invest in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches. The firm has no set number of allocations that it plans to make over the next 6-9 months but they are actively seeking new opportunities.

The firm invests in therapeutics to treat rare diseases. The firm is agnostic regarding technology type and indication areas pending the targeted market can have expedited regulatory approval through a rare/orphan status. The fund typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital company founded in 1995 and based in Northern Europe manages approximately €200 in assets, with 2 life science investment funds. The firm makes equity investments into early stage companies of up to €2 million initially and €8-€10 million of the lifetime of the investment. The firm is currently looking for companies located throughout Europe and the US and plans to make approximately 2 investments over the next 6-9 months.

The firm is looking for companies in areas of Therapeutics, Diagnostics, Medical Devices and Biotech Other. For Therapeutics and Diagnostics the firm is looking for companies with platform technologies that are anywhere from 12-36 months pre proof of concept in animal trials. Subsectors of particular interest in this areas include Immunology, Anti-Infectives, Vaccines, Ophthalmology, Orphan Indications, and Biomarkers. In areas of Medical devices the firm looks for companies around 12 months pre-proof of concept and is particularly interested in biomaterials, surface treatments, therapeutic devices, biofilms, coatings, remote patient monitoring and assisted living. In the Biotech Other space, the firm is interested in early stage companies in sectors of Agbio, Industrial Bio, Cleantech, and Nutrition. The firm is also interested in companies that are developing better methods for biosynthesis for biologics. The firm is also interested in Healthcare IT opportunities including Apps, Sensors, Databases and Systems.

 The firm values the company’s technology as it’s 1^st priority. The firm is looking for companies with platform technologies that are looking to stay a development company and build a strong pipeline of potential candidates. The firm is willing to help companies complete their management teams and looks to secure a seat on the company’s board following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a multinational conglomerate corporation seeks to invest in disruptive early stage technologies and business model innovations. The firm looks to invest in six areas including the life science space that are strategically relevant its parent company. The firm prefers to invest in Series B round or later, but it is open to consider seed and Series A round. The firm generally allocates approximately $2 million -$5 million for early-stage companies, on a case-by-case basis. Investments are typically in forms of equity, whereas other capital structures may also be considered. The firm is seeking new investment opportunities around the globe with a focus on United States, Europe, Brazil, Singapore and China.

The firm is currently looking for new opportunities in Medical Technology, Diagnostics, Specific biotech areas and Healthcare IT. In the Medtech sector, the firm is interested in companies developing Class II Medical devices with 510(K) regulatory pathways preferably in clinic. The firm focuses on companies developing dental devices, would care, coatings and diagnostic devices. In the Biotech sector, the firm focuses on companies targeting infection prevention and food safety (such as testing and hygiene monitoring products). The firm is also interested in Healthcare IT companies developing software, solutions and platforms for better clinical and financial performance.

The firm focuses on investments in private companies. The firm considers pre-revenue companies with strong and experienced management team. The firm will take a board seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hedge fund with multiple European Offices is looking to invest in growth, expansion and roll-out stage companies, primarily in Series D-E rounds, and sometimes in Series C rounds. Initial investments are typically $8-10 million. The firm is generally focused on Western Europe but is also open to opportunities in North America.

The firm’s primary investment themes are personalized medicine and agriculture. Within personalized medicine, the firm focus subsector is molecular diagnostics, but other areas of diagnostics technology may be of interest; however the firm is typically not interested in patient monitoring technologies or care management. The firm has also invested in medical devices, but is only interested in devices that are highly disruptive or which represent completely new markets. The firm will consider any indication but is particularly interested in oncology and neurology. The firm only invests in life science companies that have products which have attained approval or which are very close to approval and have significant amounts of data. 

The firm prefers to invest in companies at the early commercialization stage that have completed development of a technology but require capital to expand sales and marketing efforts. The firm is also open to early growth investments in companies with existing revenues. The firm is currently focused on investing in privately held companies but will also consider investing in publicly traded companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A VC fund with offices in the US and Asia manages roughly $70 million that it is actively seeking to invest. The initial investment size is highly variable though the firm is looking to provide up to $10+ million over the lifetime of the investment. The firm generally provides capital in the form of equity though they also have experience in working with convertible notes. The firm is interested in companies located either in the US or Asia. The firm’s primary focus is on private companies while public investments are also made selectively.

The fund is currently interested in companies developing Therapeutics, Diagnostics, Medical Devices, Healthcare IT, and R&D Services Companies. The firm is entirely opportunistic in terms of subsector and indication. In terms of phase of development, the firm is looking for companies with lead assets in the preclinical stage to companies that already have products on the market. The firm will consider companies in various stages on a case by case basis including seed financing.

The fund views the management team as one of the most important variables in selecting a potential investment. The firm looks for highly experienced and trustworthy management teams. The firm is highly interested in US based companies that are looking to expand into Asian markets or vice versa as member of the fund can add much value in these situations with their vast Asian network. However this US-Asia business development angle is not a criteria or requirement for the firm’s investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical development company seeks to acquire assets in the therapeutics sector, and form new companies to develop these assets to commercialization. The firm primarily works with biotech companies based in North America.

The firm is interested in a broad range of therapeutic assets that have some level of proof of concept data (preferably in humans); the firm’s primary area of expertise is dermatology, and assets in the inflammation and oncology sectors are also highly of interest (but not immuno-oncology). In general the firm does not invest in infectious diseases, diseases of the nervous system, mental and behavioral disorders, or disease areas that require large trial sizes such as cardiovascular disease and diabetes.

When the firm acquires an asset, the firm typically keeps on the key team members associated with that asset and works with them throughout the development process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital branch of a drug retailing chain looks to make strategic equity investments into companies of up to $5 million. The firm is generally stage agnostic although they prefer companies at or near commercialization. The firm is actively reviewing new investment opportunities and is open to consider companies from around the globe.

The firm is focused on investing in companies of mutual strategic benefit to Walgreens. This includes companies in sectors of Medical Devices, Point of Care Diagnostics, Healthcare Services, Pharmacy Innovation, and Sensors/Wearable devices. For medical devices and diagnostics the company prefers products that are near or have reached commercialization as the firm can add significant strategic value in distribution, marketing and sales. The firm is also very interested in products that will be sold directly to patients or devices/diagnostics that will be able to be used in the clinics. For wearable devices and sensors the firm is most interest in technologies with clinical value in terms of disease treatment and/or management. The firm is open to all indication types.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com